OA: Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, December 17, 2016

OA: Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment



Free Full-Text
 Next-generation/high-throughput sequencing has been used to investigate tumor evolution of specimens of high-grade serous ovarian cancer [40,48,49,51,52,53], as well as non-serous ovarian cancer lesions [40].
 It is, however, clear that overcoming disease resistance to treatment will require a diversity of approaches. Furthermore, it is critically important that the putative drivers of individual tumors uncovered in molecular studies are linked with the discovery of new single-agent and combination targeted regimens in the setting of clinical trials, such as those targeting multiple therapeutic pathways based on the specific molecular characteristics of the disease in individual patients [142,143].


 (see chart below) Figure 2. (A) Histological subtypes of ovarian cancer; and (B) widely accepted epithelial ovarian cancer classification paradigm based on clinicopathologic and molecular evidence that type I and type II tumors develop through different pathways (Kurman et al. [18]). * Indicates rare tumor; Mucinous and malignant Brenner tumors are considered to be possible exceptions that may arise from transitional cells at or close to the junction of the fallopian tube and the peritoneum.